LRRK2 and Parkinson disease: Michael J. Fox Foundation for Parkinson’s Research sponsored an observational study with the aim of optimizing an isolation protocol for cerebrospinal fluid (CSF)-derived EVs, to enrich and increase the detection of specific PD-associated mutations in LRRK2 (Leucine-rich repeat kinase 2).